Surabgene Lomparvovec (ABBV-RGX-314), Surabgene Lomparvovec (ABBV-RGX-314) clinical trials

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy

This study is looking long-term at the safety and how well a new treatment, Surabgene Lomparvovec (ABBV-RGX-314), works for wet age-related macular degeneration (nAMD). It's given as a single injection into the eye to see if it can help improve or maintain vision and reduce the need for repeat injections.